Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.10  

	

 	 	Cook Imaging

Cook Pharmaceutical Solutions
 P.O. Box 3068

Bloomington, IN 47402-3068

Phone: 812 333-0887

Fax: 812 332-3079

www.cookgroup.com

 
 

Product Development and Clinical Supply Agreement    
    

THIS
AGREEMENT is effective as of the 10th day of September 1999. 

BY AND BETWEEN:  

        BIOMIRA USA, a Corporation organized and existing under the laws of Delaware, with its principal offices located at 1002 East Park Boulevard, Cranbury, New Jersey
08512 (hereinafter referred to as "CLIENT") 

AND:  

        COOK IMAGING CORPORATION d.b.a. COOK PHARMACEUTICAL SOLUTIONS, a corporation organized under the laws of Indiana, with its principal place of business located at
927 South Curry Pike in Bloomington, Indiana 47403 (hereinafter referred to as "COOK"); 

        WHEREAS CLIENT is the owner of patents, formulations and know-how related to the pharmaceutical product "Liposomal BLP25"
(hereinafter referred to as the "Drug Product"); 

        WHEREAS COOK has the expertise and the manufacturing facility suitable for the pharmaceutical preparation and production of the Drug
Product; 

        WHEREAS, CLIENT wishes to have COOK manufacture the Drug Product and COOK wishes to supply the Drug Product to CLIENT; 

        NOW, THEREFORE, in consideration of the premises and the undertakings, terms, conditions and covenants set forth below, the parties hereto
agree as follows: 

DEFINITIONS  

        1.1   DRUG PRODUCT shall mean the pharmaceutical "Liposomal BLP25" in finished dosage form for development and/or clinical use. 

        1.2   SPECIFICATIONS shall mean those specifications set forth in the Provisional Product Specification Sheet and/or the Master
Batch Record and include Drug Product and Raw Material specifications. 

        1.3   DEVELOPMENT shall mean work necessary to develop a process to manufacture the Drug Product, and, when applicable, in full
accord with cGMP and to supply the Drug Product conforming to the Specifications. Development activities shall include, but are not be limited to, research and preparation of experimental batches and
Good Laboratory Practices ("GLP") batches in accordance with the terms set forth in the Project Plans. 

        1.4   PRODUCTION shall mean qualification of Cook quality control laboratories, qualification and/or validation of the
manufacturing process, and manufacture and delivery of the Drug Product in accordance with the cGMPs and the terms set forth in the Project Plans. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

1

 

        1.5   LABELING shall mean all labels and other written, printed, or graphic matter upon: (i) the Drug Product at any
container, carton, or wrapper utilized with the Drug Product or (ii) any written material accompanying the Drug Product, including without limitation, package inserts. 

        1.6   IND shall mean an Investigational New Drug Exemption Application for the Drug Product, as defined in the United States
Food and Drug Administration (FDA) rules and regulations, 21 CFR. 

        1.7   FDA shall mean the United States Food and Drug Administration. 

        1.8   DMF shall mean Drug Master File, as defined in the FDA rules and regulations. 

        1.9   cGMP shall mean current Good Manufacturing Practices as defined in the FDA rules and regulations, 21 CFR Parts
210-211. 

        1.10 MASTER BATCH RECORD (MBR) shall mean the formal set of instructions for the production of the Drug Product. The MBR
shall be developed and maintained in COOK's standard format by COOK, using CLIENT's master formula and technical support. 

        1.11 BULK DRUG SUBSTANCE shall mean the BLP25 Lipopeptide used as the raw materials in the Drug Product. 

        1.12 PROVISIONAL PRODUCT SPECIFICATION SHEET shall mean a listing of the analytical testing to be performed on the Bulk Drug
Substance, the Drug Product, and the stability program. 

        1.13 RAW MATERIALS shall mean Bulk Drug Substance, inactive excipients, and/or primary packaging components as listed in
Project Plans. 

        1.14 DEVELOPMENT PLAN shall mean the manual containing the parameters for the Development of Product which shall be developed
by COOK and agreed to in writing by CLIENT for Drug Product developed. Prior to commencing development hereunder for any Drug Product, COOK shall deliver two (2) signed originals of the
Development Plan to CLIENT. CLIENT shall sign both originals of the Development Plan and return one (1) fully executed original to COOK. Each fully executed Development Plan shall be
Incorporated herein by reference and made a part of this Agreement. 

        1.15 PROJECT PLAN shall mean the manual containing the parameters for the Production of Product which shall be developed by
COOK and agreed to in writing by CLIENT for each Drug Product. Prior to commencing development hereunder for any Drug Product, COOK shall deliver two (2) signed originals of the Project Plan to
CLIENT. CLIENT shall sign both originals of the Project Plan and return one (1) fully executed original to COOK. Each fully executed Project Plan shall be incorporated herein by reference and
made a part of this Agreement. 

        1.16 REGULATORY PLAN shall mean the manual containing regulatory services and support for the development and maintenance of
regulatory submissions and supporting documentation. The Regulatory Plan will be developed by COOK and agreed to in writing by CLIENT. COOK shall execute the Regulatory Plan and deliver two
(2) originals of the Regulatory Plan to CLIENT. CLIENT shall sign both originals of the Regulatory Plan and return one (1) fully executed original to COOK. Upon full execution, the
Regulatory Plan shall be incorporated herein by reference and made a part of this Agreement. 

DEVELOPMENT PROVISIONS  

        2.1   Initiation: Upon execution of this Agreement and the corresponding Development Plan and/or Project Plan for each Drug
Product, COOK shall commence Development and/or Production of such Drug Product pursuant to the timeline set forth in the Development and/or project Plans. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

2

 

        2.2   Documentation: The Master Batch Record shall be reviewed and approved by COOK and by CLIENT. Any substantive change to an
approved Master Batch Record will be reviewed and approved by COOK and by CLIENT prior to said change being implemented. Each batch of Drug Product is produced by using a copy of the Master Batch
Record. Each batch record is assigned a unique batch number. Any deviation from the specified manufacturing process must be documented in the batch record. COOK shall provide CLIENT with required
supporting documentation for the Development in a form reasonably suitable for CLIENT's submission to the FDA. In no event will COOK be responsible for supplying CLIENT with Regulatory Support
pursuant to this Agreement, except as specifically set forth in the Regulatory Plan. 

        2.3   Bulk Drug Substance Supply: CLIENT, at its sole cost and expense (including, without limitation, shipping costs), shall
supply to COOK, in a timely manner, all Bulk Drug Substance required to satisfy the terms of this Agreement. Risk of loss of Bulk Drug Substance shall at all times remain with CLIENT. CLIENT shall be
responsible for obtaining and maintaining sufficient quantities of the Bulk Drug Substance and Drug Product reserve samples as defined in Good Manufacturing Practices regulations 21 CFR
Section 211.170. 

        2.4   Supply and Testing of Raw Materials: Raw Materials as specified in each Project Plan shall be tested in accordance with
standard operating procedures or other compendia which define the sampling methodology and the analytical methods used to assure that the Raw Materials meet the Specifications. COOK and CLIENT agree
that a vendor's certificate of analysis may be relied upon by COOK in lieu of testing, provided that testing by COOK or CLIENT has validated the vendor, or at CLIENT's request. For Raw Materials
listed in Project Plans and which are not included in the current USP/NF, and for the Bulk Drug Substance supplied by CLIENT or its agents, COOK shall obtain CLIENT's approval prior to instituting any
changes to the Specifications, sampling, or test methods for that material. 

        2.5   Delivery Terms: COOK shall ship all Drug Product to CLIENT or to CLIENT's designated consignee, after satisfaction of the
conditions in Paragraph 4.1 hereto. All shipments shall be shipped FCA (Incoterms, 1990) Bloomington, Indiana. Client shall be responsible for all freight and delivery charges, including
without limitation insurance charges, and shall assume all risk of loss of the Drug Product after delivery to the designated carrier. COOK will not be responsible for environmental conditions during
shipping unless such environmental conditions during shipping are specified by CLIENT, in writing, prior to the first shipment of Drug Product. All shipping instructions of CLIENT shall be accompanied
by the name and address of the recipient and the shipping date. CLIENT shall, within fifteen (15) working days after its receipt of the executed batch record, notify COOK in writing, of any
claim relating to non-conforming Drug Product and, failing such notification, notwithstanding Paragraph 5.1 of this Agreement, CLIENT shall be deemed to have accepted the Drug
Product, and waived its right to revoke acceptance. 

        2.6   Payment for the Drug Product and Development: At the completion of each development project, COOK shall invoice CLIENT
for the Development costs, as set forth in Development Plans. Cook shall invoice client for client's purchase of the Drug Product as set forth in the Project Plans and as defined:
[+] upon client approval of the Project Plan; [+] when the product has been filled by COOK; and [+] after COOK release of the
executed batch record. The foregoing amount shall be applied to the first invoice pursuant to the terms and conditions set forth in Project Plans. Each payment shall be made by the CLIENT within
[+] days after the date of the invoice for the Drug Product and/or any other service. Payment not received within [+] days for any invoice
shall bear interest at [+] per month. 

        2.7   Scope of Professional Services: At CLIENT's written request and upon terms and conditions agreed upon by both parties,
COOK's pharmaceutical scientists may advise CLIENT with respect to 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

3

 

development
studies, formulation, primary packaging, and manufacturing process development in connection with Drug Product (the "Formulation Services"). 

        2.8   Returns: Returned Drug Product is the responsibility of CLIENT. 

TERM AND TERMINATION  

        3.1    Term:    This Agreement shall commence on the date first above written and will continue until the Development
and Production, as described in Project Plans, has been completed, unless sooner terminated pursuant to Paragraph 3.2 herein (the "Term"). 

        3.2    Termination:    This Agreement may be terminated at any time upon the occurrence of any of the following
events: 

        (a)   Default:    Upon
forty-five (45) days written notice, by either party to the other party, in the event that the other party breaches any
provision of this Agreement, and such party fails to remedy the breach prior to the expiration of the forty-five (45) day period. 

        (b)   Insolvency:    Upon
written notice by either party to the other party upon insolvency or bankruptcy of the other party, and the failure of any such insolvency
or bankruptcy of the other party to be dismissed within sixty (60) days. 

        (c)   Force
Majeure:    If, as a result of causes described in Paragraph 7.1, either party is unable to fully perform its obligations hereunder for a period
of sixty (60) consecutive days, the other party shall have the right to terminate this Agreement upon at least thirty (30) days prior written notice. 

Termination,
expiration, cancellation or abandonment of this Agreement, through any means and for any reason, shall not relieve the parties of any obligation occurring prior thereto and shall be
without the prejudice to the rights and remedies of either party with respect to any antecedent breach of any of the provisions of this Agreement or CLIENT'S purchase order issued hereunder. 

        3.3    Payment on Termination:    In the event of the termination or cancellation of this Agreement, CLIENT shall
reimburse COOK for all raw materials and components ordered prior to termination and not cancelable at no cost to COOK. CLIENT shall pay prices as described in Project Plans for (a) all
work-in-process commenced by COOK and (b) all finished goods of COOK. Except for termination in the event of a default by COOK, CLIENT shall be responsible for all other
expenses and losses incurred by COOK because of the termination. Following expiration or termination, COOK shall ship such materials to CLIENT at CLIENT's cost and per CLIENT's instructions. CLIENT
shall make payment for all expenses described in Paragraph 3.3 net [+] days from the invoice date. 

        3.4    Survival:    Sections headed Term and Termination, Warranties, Drug Product Recalls, Confidentiality, and
Indemnification shall survive the termination or cancellation of this Agreement for any reason. 

CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE  

        4.1    Certificates of Analysis:    COOK shall test, or cause to be tested, in accordance with the Specifications,
each batch of the Drug Product manufactured pursuant to this Agreement before delivery to CLIENT. A certificate of analysis for each batch delivered shall set forth the items tested, specification,
and test results. COOK shall also indicate on the final page of the batch record that all batch production and control records have been reviewed and approved by the appropriate quality control unit.
COOK shall send, or cause to be sent, such certificates to CLIENT prior to the shipment of the Drug Product (unless the product is shipped under quarantine). CLIENT shall test, or cause to be tested,
for final release, each batch of the Drug Product as meeting the Specifications. As required 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

4

 

by
the FDA (see Paragraph 5.2 below), CLIENT shall assume full responsibility for final release of each lot of the Drug Product. 

        4.2    Manufacturing Compliance:    COOK shall advise CLIENT immediately if an authorized agent of any regulatory body
visits COOK's manufacturing facility and makes an inquiry regarding COOK's method of manufacture of the Drug Product for CLIENT. Manufacturing deviations and investigations which occur during
manufacture of Drug Product and which do not cause the Production to be non-compliant with cGMPs, shall not be deemed to cause such Drug Product to be non-conforming. 

        4.3    Reserve Samples:    CLIENT shall be responsible for obtaining and maintaining sufficient quantities of the Bulk
Drug Substance and Drug Product reserve samples as defined in Good Manufacturing Practices regulations 21 CFR Section 211.170. 

        4.4    Annual Quality Review:    CLIENT shall be responsible for evaluating, at least annually, the quality standards
of the Drug Product to determine the need for changes in the Drug Product specifications, manufacturing processes, and/or controlled documents. COOK shall provide CLIENT with access to all appropriate
batch records for each batch of the Drug Product. CLIENT shall supply COOK a copy of the examination results and recommendations, if any. 

        4.5    Distribution Records:    COOK shall maintain distribution records which contain all of the appropriate
information as specified in the Good Manufacturing Practices regulations 21 CFR Section 211.196. 

        4.6    Customer Complaints:    Complaint files, as required by 21 CFR Section 211.198 of the Good Manufacturing
Practices regulations, shall be maintained by CLIENT. All complaints received by COOK shall be forwarded to CLIENT. CLIENT shall be responsible for the review of the complaint to determine the need
for an investigation as specified in 21 CFR Section 211.192, or the need to report to FDA as required by 21 CFR Section 310.305, Section 312.32, and Section 314.50
(d)(5)(vi). CLIENT shall send to COOK all Drug Product performance or manufacturing-related complaints which require investigation. COOK shall conduct an investigation for each Drug Product
performance or manufacturing-related complaint and shall report findings and follow-up of each investigation to CLIENT. CLIENT shall make these complaint files available to COOK in the
event they are required during an FDA inspection. 

        4.7    Audits:    Except with respect to information and operations which constitute COOK trade secrets, CLIENT, upon
prior written notice and during normal business hours, shall have the right to inspect COOK batch records and the portions of COOK's facility used for the Production of Drug Product once annually. If
CLIENT chooses to audit COOK more than one time in a calendar year, CLIENT agrees to reimburse COOK for COOK's reasonable expenses incurred in hosting the audit. All audited data will be treated as
Confidential Information of COOK. 

        4.8    Regulatory Compliance:    Unless otherwise stated, COOK is responsible for compliance with all Federal, State
and local laws and regulations ("Regulations") as they apply solely to COOK's pharmaceutical preparation and product facility generally and COOK shall have no responsibilities for compliance with
Regulations as they relate specifically to Drug Product. 

WARRANTIES  

        5.1    Conformity with specifications:    COOK warrants only that, at the time of manufacture, the Drug Product
(a) is prepared and tested in accordance with the Specifications, including cGMP and (b) is free of liens and encumbrances. Because of individual biological differences, no product is
100% effective under all circumstances. In addition, because COOK has no control of the conditions under which the Drug Product is used, the diagnosis of the patient before or after treatment with the
Drug Product, the method of use or administration of the Drug Product, and handling of the Drug Product 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

5

 

after
it leaves COOK's possession, COOK does not warrant either a good effect, or against an ill effect, following the use of the Drug Product. THE FOREGOING WARRANTIES ARE EXCLUSIVE AND IN LIEU OF
AND SHALL SUPERSEDE ALL OTHER WARRANTIES OF ANY KIND, WHETHER WRITTEN, ORAL, OR IMPLIED. THERE ARE NO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR OF NONINFRINGEMENT. No
representative of COOK may change any, of the foregoing warranties and CLIENT accepts the Drug Product subject to all terms hereof. 

        5.2    Non-Conforming Drug Product:    Within [+] calendar days from the
release of the executed Batch Record to CLIENT, CLIENT shall determine whether the Drug Product conforms to the Drug Product Specifications, Master Batch Record, COOK's current SOPs, and the Project
Plan (collectively the "Product Requirements"). If any batch of Drug Product conforms to the Product Requirements, CLIENT must accept the Drug Product. If CLIENT fails to notify COOK within the
[+] calendar day period that the Drug Product does not conform to the Product Requirements, then CLIENT shall be deemed to have accepted the Drug Product and waived its
right to revoke acceptance. If CLIENT believes any batch of Drug Product does not conform to the Product Requirements, it shall notify COOK by telephone including a detailed explanation of the alleged
non-conformity and shall confirm such notice in writing via overnight delivery. Upon receipt of such notice, COOK will investigate such alleged non-conformity, and
(i) if COOK agrees such Drug Product is non-conforming as a result of the negligence of COOK, deliver to CLIENT a corrective action plan within
[+] calendar days after receipt of CLIENT's notice of
non-conformity, or such additional time as is reasonably required if such investigation or plan requires data from sources other than CLIENT or COOK, or (ii) if COOK disagrees with
CLIENT's determination that the Drug Product is non-conforming as a result of the negligence of COOK, COOK shall so notify CLIENT by telephone within the
[+] calendar day period and confirm such notice in writing by overnight delivery. If the parties dispute whether the Drug Product is conforming or
non-conforming or whether the non-conformity was caused by COOK or CLIENT, samples of the Drug Product will be submitted to a mutually acceptable third party for resolution,
whose determination of conformity or non-conformity and the party responsible therefore shall be binding upon the parties. The incorrect party shall hear the costs of such third party. In
the event COOK agrees that the Drug Product is non-conforming as a result of the negligence of COOK or the third party determines that the Drug Product is non-conforming solely
as a result of the negligence of COOK, then COOK, at its expense, but subject to CLIENT, at its expense, supplying the replacement Bulk Drug Substance, and upon payment for the
non-conforming Drug Product by CLIENT, shall replace such non-conforming Drug Product within [+] calendar days from receipt of replacement Bulk
Drug Substance from CLIENT, or will refund the purchase price of the non-conforming Drug Product. 

        5.3    Compliance:    CLIENT assumes responsibility for all contact with the FDA and other regulatory bodies,
pertaining specifically to Drug Product. 

        5.4    Limitation of Remedies and Damages:    Except for COOK's obligation under section 10.2, CLIENT's sole
and exclusive remedy for any claim arising by reason of or in connection with the sale, purchase, or delivery or use of Drug Product, regardless of whether such claim is based on tort law, breach of
contract, breach of warranty or any other legal theory ("claim") shall be, at COOK'S option, the replacement of the Drug Product (subject to CLIENT's supply, at its cost, of replacement Bulk Drug
Substance) or the return of the purchase price for such Drug Product. Under no circumstances shall COOK be liable for loss of use, lost profits or any other collateral, special, consequential other
damages, losses, or expenses in connection with or by reason of any claim. Any lawsuit asserting any claim must be brought by CLIENT against COOK within two (2) years after delivery of Drug
Product to CLIENT or such claim shall be forever barred. 

        5.5    Waiver of Claims:    In connection with providing Formulation Services, COOK represents only that it will use
reasonable care in providing such information solely as it relates to development 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

6

 

studies,
formulation, primary packaging and manufacturing process development. COOK makes no representation or warranty, and CLIENT expressly waives all claims against COOK, its agents or employees,
arising out of or in connection with any claims relating to the stability, efficacy, safety, or toxicity of Drug Product developed, formulated, packaged or manufactured in accordance with the
Formulation Services provided by COOK. 

DRUG PRODUCT RECALLS  

        6.1    Drug Predict Recalls:    In the event: (a) any government authority issues a request, directive or order
that the Drug Product be recalled, or (b) a court of competent jurisdiction orders such a recall, or (c) CLIENT reasonably determines that the Drug Product should be recalled because the
Drug Product does not conform to Specifications, CLIENT shall take appropriate corrective actions. In no event, however, shall COOK have responsibility for regulatory compliance in connection with any
recall, except to the extent as required by law. All costs and expenses incurred in connection with such recall shall be the responsibility of CLIENT unless caused solely by the negligence of COOK. In
no event shall COOK have any liability for consequential damages incurred by CLIENT which arise out of, or in connection with, any Drug Product recall. 

FORCE MAJEURE; FAILURE TO SUPPLY  

        7.1    Force Majeure Events:    Failure of either party to perform under this Agreement (except the obligation to make
payments) shall not subject such party to any liability to the other if such failure is caused by acts of God, fire, explosion, flood, drought, war, riot, sabotage, embargo, strikes or other labor
trouble, compliance with any order or regulation of any government entity, or by any cause beyond the reasonable control of the affected party, whether or not foreseeable, provided that written notice
of such event is promptly given to the other party. 

        7.2    Failure to Supply:    If COOK fails to supply all or any material part of the Drug Product ordered by CLIENT,
CLIENT may require COOK to supply the undelivered Drug Product or a lesser quantity at a future date agreed upon by CLIENT. The provisions of this Paragraph 7.2 shall be without prejudice to
CLIENT's rights under Paragraph 3.2 and remedies provided for thereunder. 

IMPROVEMENTS  

        8.1    Changes by CLIENT:    CLIENT must approve, in writing, the Master Batch Record prior to the initial date of
manufacture and the Provisional Product Specification Sheet, at least [+] prior to the initial date of manufacture. If CLIENT requests a change to the Master Batch Record
and/or the Provisional Product Specification Sheet and COOK agrees that such change is feasible with regard to the manufacture of the Drug Product, such change shall be incorporated within the Master
Batch Record and/or Specifications pursuant to a revision of the Master Batch Record and/or Provisional Product Specification Sheet. The price of the Drug Product shall be adjusted for such change,
and CLIENT shall pay COOK the costs associated with such change, including any development work, if necessary, based upon COOK's then-prevailing development rates. Such revisions, prices
and costs shall be set forth in a written amendment to this Agreement. It is the responsibility of CLIENT to insure that proper regulatory agencies approve the suggested changes. 

        8.2    Changes by COOK:    COOK agrees that any changes developed by COOK which may be incorporated into the Drug
Product shall be set forth in a revision of the Master Batch Record and Provisional Product Specification Sheet, if applicable, prior to such incorporation. It is the responsibility of CLIENT to
ensure that proper regulatory agencies approve the suggested changes. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

7

 

CONFIDENTIALITY  

        9.1   This
Agreement, by reference, incorporates the Confidentiality Agreement signed by CLIENT and COOK on September 26, 1997, and is made a part hereof as though
fully set forth herein. 

        9.2   Any
invention made, conceived or reduced to practice by COOK in connection with the performance of the obligations under this Agreement, during the term of this
Agreement or thereafter, whether derived from COOK or CLIENT, shall be considered confidential information and shall be the exclusive property of COOK; provided, however, that any invention made,
conceived of, or reduced to practice during the Term of this Agreement, of [+] shall promptly sign and deliver any and all documents or information necessary for the securing
of such invention in any country as determined by the owner. 

        9.3   The
parties agree that contents of this Agreement (including any attached schedules) shall not be disclosed to any third party without the prior written consent of the
other party except that it may be disclosed to the following, subject to the agreement to maintain the contents of this Agreement in confidence: (1) the controlling companies of the parties,
(ii) the companies controlled by the parties, (iii) governmental regulatory agencies, including, but not limited to, environmental protection authorities, (iv) contract
laboratories, and (v) suppliers (for DMF authorization). 

        9.4   Upon
termination of this Agreement for whatever reason, each party shall return to the other all originals, copies, and derivative forms of disclosed or developed
information relating to the purpose of this Agreement except that one copy of such information may be retained by the receiving party as required by regulatory law for future reference or for archival
purposes. The confidential information shall remain confidential and not be disclosed by the receiving party for a period of [+] years following the date of expiration
or termination of this Agreement. 

INDEMNIFICATION  

        10.1    Indemnification by CLIENT:    CLIENT shall indemnify and hold COOK (and any parent, subsidiary, or affiliate
company or corporation, and their officers, directors, shareholders, agents, and the employees and insurers of any of them and/or their successors and assigns thereto, collectively the "Affiliates"),
free and harmless from any and all claims, demands, liability, losses, actions, or any fines or penalties, and any and all expenses associated therewith (including without limiting the generality of
the foregoing, defense costs and attorney's fees), arising out of or in connection with, are the result of, or are otherwise related to: (i) any act or omission of CLIENT; (ii) the
promotion, distribution, use, misuse or sale of the Drug Product (including, without limiting the generality of the foregoing, any claims, express, implied or statutory, made as to the efficacy or
safety thereof); (iii) any Drug Product labeling or packaging; (iv) CLIENT's compliance or non-compliance with any applicable Federal or State laws or regulations;
(v) any failure of CLIENT to perform, in whole or in part, any of its obligations hereunder, or (vi) CLIENT's manufacture or handling of the Bulk Drug Substance, unless caused solely by
the acts or omissions of COOK. 

        10.2    Indemnification by COOK:    COOK will indemnify and hold CLIENT and its Affiliates free and harmless against
any and all claims, demands, actions or causes of action, and any and all expenses associated therewith (including, without limiting the generality of the foregoing, defense costs and attorneys fees),
for damages on account of personal injury (including death) or property damage caused solely by the acts or omissions of COOK. 

        10.3    Patent Indemnity:    CLIENT further warrants that manufacture, use and sale of the Drug Product and Bulk Drug
Substance will not infringe any patent or other proprietary rights and that 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

8

 

CLIENT
will indemnify, defend and hold COOK and its Affiliates free and harmless from any damage, judgment, liability, loss, cost or expense, including legal expenses, arising from claims that the
manufacture, use or sale of the Drug Product or Bulk Drug Substance infringe patent or other proprietary rights of a third party. 

        10.4    Conditions of Indemnification:    If either party seeks indemnification from the other under Paragraphs 10.1,
10.2, or 10.3, it shall promptly give written notice to the other party of any such claim or suit threatened, made or filed against it, which forms the basis for such claim of indemnification and
shall cooperate fully with the other party in the defense of all such claims or suits. No settlement or compromise shall be binding on a party hereto without its prior written consent. 

GENERAL PROVISIONS  

        11.1    Notices:    Any notice permitted or required by this Agreement may be sent by facsimile with the original
document being sent by certified (or registered) mail, return receipt requested, or overnight delivery and shall be effective when received (or refused) via facsimile or mail or overnight if faxed and
sent and addressed as follows (or to such other facsimile number or address as may be designated by a party in writing): 

	If to CLIENT:	 	Biomira USA, Inc.

1002 Eastpark Boulevard

Cranbury, NJ 08512

Attn: Laura Pflug, Technical Operations and Quality
	

 	
 	

Telephone: (609) 655-5300

Facsimile: (609) 655-1755
	

If to COOK:	
 	

Cook Imaging Corporation

927 South Curry Place

Bloomington, IN 47403

Attn: Alisa Wright, Business Affairs Manager
	

 	
 	

Telephone: (812) 333-0887

Facsimile: (812) 332-3079

        For
specific inquiries, the following COOK responsible parties may be contacted directly: 

	Project Manager	 	Wendy Wilson
	

Quality Control Manager	
 	

Tami Stackhouse
	

Materials Manager	
 	

Robert Stoner
	

Quality Assurance Manager	
 	

Jennifer Walls

        For
specific inquiries, the following CLIENT responsible parties may be contacted directly: 

	Project Manager	 	Bill Reilley, Biomira USA Inc.
	

Quality Control Manager	
 	

Gerry Murphy, Biomira Inc. (780) 450-3761 × 318
	

Materials Manager	
 	

Ray Fermimore, Biomira USA Inc.
	

Quality Assurance Manager	
 	

Joseph Wu, Biomira Inc. (780) 450-3761 × 319

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

9

 

        11.2    Entire Agreement: Amendment:    The parties hereto acknowledge that this Agreement sets forth the entire
agreement and understanding of the parties and supersedes all prior written or oral agreements or understandings with respect to the subject matter hereof. No modification of any of the terms of this
Agreement, or any amendments thereto, shall be deemed to be valid unless in writing and signed by an authorized agent or representative of both parties hereto. No course of dealing or usage of trade
shall be used to modify the terms and conditions herein. 

        11.3    Waiver:    None of the provisions of this Agreement shall be considered waived by any party hereto unless such
waiver is agreed to, in writing, by authorized agents of both parties. The failure of a party to insist upon strict conformance to any of the terms and conditions hereof, or failure or delay to
exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any party hereto. 

        11.4    Obligations to Third Parties:    Each party warrants and represents that this Agreement is not inconsistent
with any contractual obligations, expressed or implied, undertaken with any third party. 

        11.5    Assignment:    This Agreement shall be binding upon and inure to the benefit of the successors or permitted
assigns of each of the parties and may not be assigned a transferred by either party without the prior written consent of the other, which consent will not be unreasonably withheld or delayed, except
that no consent shall be required in the case of a transfer to a wholly-owned subsidiary or transaction involving the merger, consolidation or sale of substantially all of the assets of the party
seeking such assignment or transfer and such transaction relates to the business covered by this Agreement and the resulting entity assumes all the obligations under this Agreement. 

        11.6    Independent Contractor:    COOK shall act as an independent contractor for CLIENT in providing the services
required hereunder and shall not be considered an agent for joint venture with CLIENT. Unless otherwise provided herein to the contrary, COOK shall furnish all expertise, labor, supervision, machining
and equipment necessary for performance hereunder and shall obtain and maintain all building and other permits and licenses required by public authorities. 

        11.7    Governing Law:    This Agreement is subject to and shall be governed by the laws of the State of Indiana. 

        11.8    Severability:    In the event that any term or provision of this Agreement shall violate any applicable
statute, ordinance, or rule of law in any jurisdiction in which it is used, or otherwise be unenforceable,
such provision shall be ineffective to the extent of such violation without invalidating any other provision hereof. 

        11.9    Headings, Interpretation:    The headings used in this Agreement are for convenience only and are not part of
this Agreement. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

10

 

        IN
WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their duly-authorized representatives as of the date first above written. 

	BIOMIRA USA, Inc.	 	COOK IMAGING CORPORATION

d.b.a. COOK PHARMACEUTICAL SOLUTIONS
	

/s/ Mircea Popescu
 Authorized Signature	
 	

/s/ Alisa K. Wright
 Authorized Signature
	

Mircea Popescu
 Printed Name	
 	

Alisa K. Wright
 Printed Name
	

09-13, 1999
 Date	
 	

9/10/99
 Date

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

11

  

October 17,
2005 

Baxter
Pharmaceutical Solutions LLC

927 South Curry Pike

Bloomington, Indiana

47403 

ATTENTION:
Dean LaPlante, Project Manager 

	Re:
	Addendum to Product Development and Clinical Supply Agreement, dated September 10, 1999, as amended on May 3, 2004 (the
"PDCS"")

        This
addendum is to serve as acknowledgement of receipt of equipment owned by Biomira Inc. as listed in Attachment "A", subject to the terms and conditions listed below 

Terms and Conditions:  

	1)
	Equipment
will be loaned to Baxter Pharmaceuticals for the purposes of manufacturing of BLP-25 and/or the placebo for Biomira Inc. pursuant to the PDCSA, and subject
to the terms and conditions of the PDCSA.

	2)
	Baxter
will return the equipment to Biomira Inc. within [+] days of receipt of a written request by Biomira.

	3)
	The
equipment will remain at the Baxter premises in Bloomington, Indiana and will not be removed, dismantled, or loaned to any other persons, without written consent of an authorized
representative from Biomira Inc.

	4)
	Baxter
will ensure reasonable due care of the equipment while it is in their possession.

	5)
	The
equipment shall at all times remain the property of Biomira, and Baxter shall have no liabilities or obligations with respect to the equipment except as provided in
Article 10 of the PDCSA. 

        Please
acknowledge your agreement to the terms and conditions above, by signing in the space below and returning this letter to Biomira Inc. 

	Yours truly	 	 	 
	

/s/ Edward Taylor
 Edward Taylor,

CFO and VP Finance and Administration Biomira Inc.	
 	

 	

 
	

Terms and conditions above agreed to by:	
 	

 	

 
	

/s/ Kelly L. Zaleski, Ph.D.
 Authorized Representative of Baxter Pharmaceuticals

Kelly L. Zaleski, Ph.D.

Sr. Director, Pharm Services	
 	

 	

 

BIOMIRA
INC. 2011 - 94 St. Edmonton, AB, Canada T6N 1H1    Tel: (780) 450-3761    Fax: (780) 463-0871

http://www.biomira.com 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

Biomira
Inc 

Attachment
"A" 

October 17,
2005 

	Biomira Identification Number
 
	 	Serial Number
	 	Equipment Description

	BIO-1010	 	N/A	 	15-L Jacketed Bioreactor (includes vessel, headplate and lipseal stirrer assembly)
	

BIO-1017	
 	

N/A	
 	

15-L Jacketed Bioreactor (includes vessel, headplate and lipseal stirrer assembly)
	

BIO-1019	
 	

N/A	
 	

5-L Jacketed Bioreactor (includes vessel, headplate and lipseal stirrer assembly)
	

EL-2093	
 	

P05257/17	
 	

ADI 1032 Stirrer Speed Controller (15-L Bioreactor)
	

EL-2098	
 	

P06175/32	
 	

Stirrer Speed Controller (5-L Bioreactor)
	

EL-3000	
 	

P14884/9	
 	

ADI 1032 Stirrer Speed Controller (15-L Bioreactor)
	

STIR-2030	
 	

P01417/3	
 	

P1000 Stirrer Motor (15-L Bioreactor)
	

STIR-2035	
 	

PO4600/14	
 	

P140 Stirrer Motor (5-L Bioreactor)
	

STIR-2037	
 	

P00664/10	
 	

P1000 Stirrer Motor (15-L Bioreactor)
	

TANK-1004	
 	

 	
 	

50-L Dedicated Stainless Steel INOVA Intermediate Tank
	

TANK-1005	
 	

TC6253	
 	

60-L Pressure Vessel
	

MISC-2105	
 	

N/A	
 	

Inova filling parts

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

QuickLinks

Product Development and Clinical Supply AgreementQuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.11  

 
 

AMENDED AND RESTATED LICENSE AGREEMENT
  dated 14th November 2000    

BETWEEN:

        (1)   Imperial Cancer Research Technology Limited, registered in England and Wales under number 1662284 whose registered office
is at Sardinia House, Sardinia Street, London WC2A 3NL, England ("ICRT") 

        (2)   Biomira Inc, a corporation having an office at Edmonton Research and Development Park, 2011-94 Street,
Edmonton, Alberta T6N 1H1, Canada ("Biomira"). 

1.     INTRODUCTION  

	1.1
	The
terms defined in clause 2 of this Agreement shall have the same meanings in this Introduction.

	1.2
	ICRT
is a company wholly owned by ICRF and, by arrangement with ICRF, owns and is responsible for the management and exploitation of ICRF technology.

	1.3
	ICRT
is the owner of an invention, made at ICRF, relating to polymorphic epithelial mucin peptide in respect of which ICRT has made certain patent applications brief details of which
are given in Schedule 1.

	1.4
	Pursuant
to the Original License, ICRT granted to Biomira the option right to be granted an exclusive license under the patents and certain other defined intellectual property rights
owned by ICRT relating to the said invention to develop and commercialise licensed products in a specified field of use. Biomira exercised such option right and is developing, among other things, a
vaccine product known as BLP25 Vaccine which incorporates the said invention.

	1.5
	Biomira
has requested that the royalty provisions be restructured in light of the possibility that Biomira may have to pay a running royalty on sales of Licensed Product in the USA to
both ICRT under the Licensed Patents and Dana Farber under the DF Patents. Having reviewed the Original License the parties also wish to take this opportunity to amend the Original License as is
necessary to reflect the current circumstances and change certain other terms thereof. Therefore, the parties have agreed to amend and restate the Original License in the manner set forth in this
Agreement and this amended and restated Agreement shall from and after the Effective Date supercede the Original License in all respects. 

        NOW
THEREFORE in consideration of the premises and of the mutual covenants and agreements contained in this Agreement and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties covenant and agree as follows: 

2.     INTERPRETATION  

	2.1
	In
this Agreement: 

        "Affiliate" means, in relation to either party, a person which controls that party, or is controlled by that party or by a person which
controls that party and for these purposes a person controls another person if, either directly or indirectly through one or more other intermediaries, it can: 

	X
	exercise
a majority of the votes attached to the voting stock, equity or income interest in such other person; or 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

 

	X
	appoint
or remove a majority of the board of directors of such other person: 

        "Biomira Information" means any and all information and technology which is applied to or derived from activities conducted by or on
behalf of Biomira with respect to the Peptide or Licensed Product; 

        "Business Day" means a day on which ordinary banks are open for over the counter business in London and Edmonton; 

        "Currency" means pounds sterling; 

        "DF Licensed Product" means a product whose manufacture, use or sale in the United States: 

	(a)
	is
covered by a Valid Claim of the DF Patents; and

	(b)
	is
not covered by a Valid Claim of the Licensed Patents; 

        "DF Patents" means United States Patent numbers [+] and [+] together with any extension,
reissue, division, continuation, continuation in part or re-examination of such patent and any patent of addition or similar rights based on any such patents and claiming priority from
such patents; 

        "Effective Date" means the date of this Agreement; 

        "Expert" means a person agreed to by the parties or in the absence of agreement, a person nominated by the then President of the Institute
of Chartered Accountants in England and Wales; 

        "Field" means the treatment or diagnosis of cancer: 

        "First Commercial Sale" means, with respect to a particular Licensed Product, the first commercial Sale after the date the New Drug
Application, Product License Application or equivalent governmental application for such Licensed Product is approved; 

        "Gross Sales" means the total amount received; 

        "ICRF" means Imperial Cancer Research Fund, a charity registered under number 209631 of 61 Lincoln's Inn Fields, London,
WC2A 3PX; 

        "ICRT Licensed Product" means, with respect to a particular country or territory, any product which incorporates Peptide and is approved
by an appropriate regulatory or governmental authority for commercial sale in the Field whose manufacture, use or sale: 

	(a)
	is
covered by a Valid Claim of the Licensed Patents in such country or territory; and

	(b)
	is
not covered by a Valid Claim of the DF Patents; 

        "ICRT/DF Licensed Product" means any product which incorporates Peptide and is approved by an appropriate regulatory or governmental
authority for commercial sale in the Field whose manufacture, use or sale in the United States: 

	(a)
	is
covered by a Valid Claim of the Licensed Patents in the United States; and

	(b)
	is
covered by a Valid Claim of the DF Patents; 

        "ICRT Patent Applications" means the patent applications details of which are given in Schedule 1; 

        "Intellectual Property" means any form of intellectual property right including without limitation any Patent and copyright; 

        "Kit" means a combination package containing the Licensed Product with other products; 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

2

 

        "Licensed Patents" means the ICRT Patent Applications and patents, details of which are given in Schedule 1, any patent obtained in
pursuance of any such application, any extension, reissue, division, continuation, continuation-in-part or re-examination of any such application or patent and any
patent of addition or similar rights based on any such application or patent and claiming priority from any patent or patent application details of which are given in Schedule 1; 

        "Licensed Product" means an ICRT Licensed Product, a DF Licensed Product and/or an ICRT/DF Licensed Product; 

        "Licensed Product royalty" means royalties' payable pursuant to clause 5.4; 

        "Major Markets" means the United States, United Kingdom, Germany, France, Italy and Spain; 

        "Net Sales Value" means, in relation to the item in question: 

	(a)
	where
the item is sold by Biomira, any of its Affiliates or any sublicensee of such person to a third party (other than between Biomira, any of its Affiliates and any sublicensee of
such person) on arm's length terms, the Gross Sales less the following:

	(i)
	any
sales tax (including without limitation any value added, goods and services, retail or other similar tax), excise tax, customs duty and any other tax, duty or levy,

	(ii)
	any
packaging, packing, freight, warehousing, carriage and insurance charges,

	(iii)
	any
provision made, acting reasonably and in accordance with good accounting practise, for bad or doubtful accounts relating to such item,

	(iv)
	any
credits or refunds actually allowed for spoiled, damaged, outdated or returned merchandise, with transportation thereon, and

	(v)
	any
normal trade, quantity, and/or cash discounts or rebates granted to the customer;

	(b)
	where
the item in question is not in the first instance sold by Biomira, its Affiliates or any sublicensee of such person to a third party on arm's length terms but is subsequently
sold by Biomira, its Affiliates or any sublicensee to a third party on arm's length terms, the Gross Sales under such arm's length sale, calculated in accordance with paragraph (a);

	(c)
	where
the item in question is not at any time sold by Biomira, any of its Affiliates or any sublicensee of such person to a third party on arm's length terms, but is sold between
Biomira, its Affiliates and any sublicensee of such person or is used by Biomira, its Affiliates or any sublicensee of such person for commercial purposes, or is otherwise disposed of on a commercial
basis, other than for sale at any time to a third party on arm's length terms as contemplated by (a) or (b) above, the gross amount that is attributed by Biomira, its Affiliates and/or
any sublicensee of such person, acting reasonably, to such sale, use or disposition, calculated in accordance with paragraph (a) above; 

provided
that where Licensed Product is sold or used or otherwise disposed of on a commercial basis as part of a Kit, then the Net Sales Value of such Licensed Product for the purposes of this
Agreement shall be determined by the following applicable method: 

	(i)
	By
the following formulae: 

A × B/(B + C) Where:

A =
the Net Sales Value of the Kit (determined in accordance with the above paragraphs); and 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

3

 

B =
the Net Sales Value of the Licensed Product contained in such Kit if the Licensed Product were sold separately (determined in accordance with the above paragraphs); and 

C =
the sum of the Net Sales Values of the other products in such Kit if each were sold separately (determined in accordance with the above paragraphs); or 

	(ii)
	If
no such separate sales are made of the Licensed Product or the other products comprising the Kit during the relevant Quarter, Biomira shall notify ICRT and the
parties shall agree a method for calculating the Net Sales Value of the Licensed Product as shall be fair and reasonable. In the absence of agreement, either party may refer the dispute to the Expert
for determination, and in the absence of manifest error, the decision of such Expert shall be final and binding on the parties. 

        "New MUC1 Invention" means any invention made by or under the supervision of Dr. Joyce Taylor-Papadimitriou pertaining to: 

	(i)
	MUC1
core protein peptide, polypeptide, protein or glycosylated forms thereof or any chemically modified or conjugated derivative thereof; and

	(ii)
	methods
of making and using any MUC1 core protein peptide, polypeptide, protein or glycosylated forms thereof or any chemically modified or conjugated derivative
thereof 

for
the detection, evaluation, prevention and/or treatment of cancer; 

        "Original License" means the license agreement between Biomira and ICRT dated 24th September 1991, as amended by an
amending agreement dated 31st January 1995 and a second amending agreement dated 5th November 1999, relating to the Peptide; 

        "Patent" means any patent application or patent, including any extension, supplementary protection certificate, reissue, division,
continuation, continuation-in-part or re-examination of any such application or patent, and any patent of addition or similar rights based on any such application
or patent; 

        "Peptide" means any peptide, polypeptide or protein or glycosylated forms thereof or any chemically modified or conjugated derivative
thereof which is covered by a Valid Claim of the Licensed Patents; 

        "Quarter" means a calendar quarter, being a three monthly period commencing on the first day of any of the months of January, April, July,
and October in any year and "Quarterly" has a corresponding meaning; 

        "royalties" means any royalties payable pursuant to this Agreement including Licensed Product royalty and Sublicense Revenue royalty; 

        "Sale" includes sale, use for commercial purposes or other disposal on a commercial basis and "Sold" has a corresponding meaning; 

        "Sublicense Revenue" means any monies received from time to time by Biomira or its Affiliates from a non-Affiliate of Biomira
under or in respect of any sublicense granted by Biomira or its Affiliates under this Agreement (e.g. license issue fees, milestone payments) but excluding any of the following paid under or in
connection with such sublicense: 

	(a)
	all
royalties or other similar payments on Sales of Licensed Product;

	(b)
	any
and all financial contributions to costs of research and development, clinical trials, regulatory approval and/or compliance whether past, present or future of a product that
incorporates Peptide and is intended for commercial sale as a Licensed Product; 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

4

 

	(c)
	any
sales tax (including without limitation any value added, goods and services, retail or other similar tax), excise lax, customs duty and any other tax, duty or levy; 

        "Sublicense Revenue royalties" means royalties payable pursuant to clause 5.1; 

        "Term" means the period during which this Agreement continues in force pursuant to this Agreement; 

        "Territory" means all countries and territories of the world; 

        "Valid Claim" means, with respect to a particular country or territory, a claim of any Patent which has not expired, been withdrawn,
abandoned or surrendered or been refused, revoked or held invalid in an unappealed or unappealable final decision rendered by a court of competent jurisdiction in the relevant country or territory; 

        "Year" means a calendar year, and "Yearly" has a corresponding meaning. 

	2.2
	Unless
the context otherwise requires, each reference in this Agreement to:

	(a)
	'this Agreement' is a reference to this Agreement and each of the Schedules, as amended or supplemented at the relevant time;

	(b)
	a
Schedule is a reference to a schedule to this Agreement;

	(c)
	a
clause or a paragraph is a reference to a clause of this Agreement (other than the Schedules) or a paragraph of the relevant Schedule;

	(d)
	any
reference to the parties includes a reference to their respective successors in title and permitted assignees;

	(e)
	any
reference to a person includes any body corporate, unincorporated association, partnership or other legal entity;

	(f)
	the
singular includes the plural and vice versa;

	(g)
	words
importing any gender include any other gender;

	(h)
	a
statute or a provision of a statute is a reference to that statute or provision as amended or re-enacted at the relevant time;

	(i)
	'writing'
or any cognate expression includes a reference to any communication effected by facsimile transmission or similar means (where such communication has been served in
accordance with clause 15).

	2.3
	The
headings in this Agreement are for convenience only and shall not affect its interpretation. 

3.     GRANT OF LICENSE  

	3.1
	ICRT
hereby grants to Biomira, subject to the provisions of this Agreement, an exclusive, worldwide license under the Licensed Patents to develop, make, have made, possess, utilize,
sell, have sold and otherwise exploit the ICRT Licensed Products and ICRT/DF Licensed Products (or products which would be such ICRT Licensed Products or ICRT/DF Licensed Products if regulatory and/or
governmental approval were obtained) in the Territory. For the avoidance of doubt, the license under the Licensed Patents does not include any right to manufacture or sell products incorporating
nucleic acid encoding MUC1.

	3.2
	Biomira
shall be entitled to exercise the rights granted under clause 3.1 by itself or through any of its Affiliates, provided that Biomira shall at all times during the Term
ensure the observance and performance by every such Affiliate of the provisions of this Agreement and shall be liable to 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

5

 
	

	ICRT
for any breach by such Affiliate of any of the provisions of this Agreement, as if the breach had been that of Biomira.

	3.3
	Biomira
and its Affiliates shall be entitled to grant sublicenses in respect of the rights granted under this Agreement, provided that:

	(a)
	Biomira
and its Affiliates shall be entitled to do so only with the prior written consent of ICRT, such consent not to be unreasonably withheld and, such consent of ICRT shall be
deemed to have been given if Biomira or the Affiliate of Biomira in question has not received written notification to the contrary from ICRT within thirty (30) days of ICRT's receipt of the
request therefor;

	(b)
	the
royalties payable under the sublicense in respect of Licensed Product shall not be more favourable to any sublicensee than to Biomira under clauses 5.4 and 5.6 of this Agreement
except as may be agreed upon in writing by ICRT, acting reasonably;

	(c)
	any
sublicense granted by Biomira or any of its Affiliates shall not permit further sublicensing without the prior written consent of ICRT, such consent not to be unreasonably
withheld;

	(d)
	any
sublicense shall be expressed to terminate automatically on the termination of this Agreement for any reason, subject to the following. Any sublicensee who wishes to continue its
sublicense must so advise ICRT in writing within thirty (30) days of the sublicensee's receipt of written notice of the termination of Biomira's license and subject to the sublicensee's
agreement to assume relative to ICRT, all the obligations, including payment, contained in the sublicense agreement with Biomira, ICRT shall continue the sublicense provided that:

	(i)
	such
sublicensee is not in breach of the sublicense agreement;

	(ii)
	such
sublicense agreement, with respect to the subject matter of such sublicense, is on terms no less favourable to ICRT than the terms of this Agreement, and

	(iii)
	ICRT
does not have reasonable cause to decline to continue such sublicense agreement; and

	(e)
	Biomira
shall be responsible for ensuring the sublicensee's compliance with the terms of this Agreement to the extent that they can be applied to the activities of the sublicensee.

	3.4
	ICRT
reserves to itself:

	(a)
	all
rights in respect of Peptide and the Licensed Patents outside the Field, except as expressly provided for under this Agreement; and

	(b)
	without
limitation to the generality of clause 3.4(a), the right, for itself and ICRF, to make, possess and use Peptide and the Licensed Patents in the Field for the purposes
of non-clinical research only, and not for any commercial purpose.

	3.5
	Upon
request by Biomira, ICRT shall ensure that its staff and the staff of ICRF provide reasonable cooperation to Biomira in its efforts to seek regulatory and governmental approval
of ICRT Licensed Products and ICRT/DF Licensed Products (or products which would be such Licensed Products if regulatory and/or governmental approval were obtained) and Biomira shall reimburse
ICRT/ICRF for reasonable out-of-pocket expenses incurred in connection with the foregoing which shall, for the avoidance of doubt, exclude wages and salaries incurred by ICRT
or ICRF in connection therewith. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

6

 
	3.6
	

	(a)
	In
respect of the right of ICRT (or ICRF) in any Patent claiming any New MUC1 Invention, neither ICRT, ICRF nor any Affiliate or licensee shall enforce the same against Biomira, its
Affiliates or sublicensees to the extent that such Patent would dominate the practise of or prevent them from exercising the rights granted to Biomira under this Agreement. This provision shall
survive the expiry of this Agreement by effluxion of time.

	(b)
	Subject
to the other provisions of this clause 3.6(b), in respect of any Patent owned exclusively by ICRT (or ICRF) claiming a New MUC1 Invention, ICRT shall, as soon as
reasonably practicable, advise Biomira in writing of any such Patent and offer Biomira the first right to negotiate to obtain a license in respect of such Patent in the Field ("the first notice").
Within [+] days of receipt of the first notice, Biomira shall notify ICRT in writing ("the second notice") whether or not it wishes to enter into negotiations for such
license. If Biomira elects to enter into negotiations, the parties will negotiate in good faith the terms and conditions for the grant to Biomira of the said license. Without limitation, such license
shall include provisions for royalty and other payments to ICRT and such other terms and conditions as are customary for such licenses. If the parties do not agree upon the terms for the grant of a
license to Biomira of such Patent within [+] months of receipt by ICRT of the second notice, ICRT shall have no further obligation to Biomira with regard to such Patent,
subject to the following. Unless Biomira has indicated that it no longer has any interest in such Patent, if ICRT intends to grant a license to such Patent to any third party on terms which
collectively are more favourable from the licensee's perspective than the terms last offered to Biomira by ICRT, ICRT shall give Biomira first right of refusal to accept such better terms before
proceeding with the third party. If Biomira does not accept such better terms and proceed to execute an agreement reflecting such terms within [+] days of ICRT's notice,
ICRT shall be free to proceed with the third party. However, this clause 3.6(b) is subject always to any third party rights in respect of any such Patent granted by ICRT and/or ICRF in
connection with the project "Development of a cancer vaccine combining DNA and specific glycoprotein/glycopeptide formulation of a tumour antigen" funded by the European Community under contract no.
QLK3-CT-19999-00217, and in the event of any inconsistency or conflict between the provisions of this clause 3.6(b) and such third party rights, the latter
shall prevail.

	3.7
	Biomira
shall retain all property rights including, but not limited to Patent rights, to all information and biological materials developed by Biomira and/or its Affiliates and
collaborators pursuant to this Agreement or amendments related thereto. The foregoing rights and all Biomira Information shall be the sole and exclusive property of Biomira, without obligation to ICRT
except so far as royalties payable to ICRT, if any, pursuant to this Agreement. 

4.     PERFORMANCE  

	4.1
	Biomira
shall use reasonable diligence to evaluate, develop, commercialise, promote and sell Licensed Products throughout the Territory subject to then existing regulatory and
economic conditions.

	4.2
	On
1st January each year during the Term Biomira shall submit to ICRT annual written reports providing a summary of Biomira's evaluation activities, development
activities, governmental filings, and activities, if any, relating to marketing of Licensed Product(s) in given countries. Such reports will include key milestones and target dates for their
achievement.

	4.3
	ICRT
shall have the right to make comments upon such reports, and Biomira shall use reasonable endeavours to make such modifications to its developmental, evaluation, and marketing
activities consistent with reasonable scientific and business practice based on such comments, as Biomira in its sole discretion shall decide. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

7

 
	4.4
	Not
more frequently than at Yearly intervals, ICRT may serve written notice that, in the opinion of ICRT, Biomira is not using reasonable diligence according to clause 4.1 or
achieving the milestones according to clause 4.2. Within ninety (90) days of the date of receipt of such notice by Biomira, Biomira shall have the right to prove to the satisfaction of
ICRT, acting reasonably, that it has been diligent in the development, clinical testing and registration and, when appropriate, promotion and commercialization of Licensed Products or provide just
cause why any such obligations or milestones have not been achieved.

	4.5
	If
ICRT has not been reasonably satisfied that Biomira has been diligent or provided just cause why any obligations or milestones have not been achieved, then the parties shall
promptly meet to discuss means by which Biomira's performance may be improved. The parties will discuss and agree upon a reasonable plan of action ("Improvements Action Plan") to be followed by
Biomira to improve its performance and Biomira shall use its reasonable commercial efforts, based on reasonable business considerations, to implement the Improvements Action Plan.

	4.6
	At
any time after the expiry of the first anniversary of the adoption of the Improvements Action Plan but prior to the completion or expiry thereof, ICRT may serve written notice to
Biomira that in the opinion of ICRT, acting reasonably, the actions stipulated in such Plan have not been implemented. If within ninety (90) days following receipt by Biomira of such written
notice a reasonable person would not be reasonably satisfied that Biomira is meeting its diligence obligations according to clause 4.1 or provided just cause why it has not, then, at ICRT's
discretion, and upon written notice to Biomira:

	(a)
	the
grant under clause 3.1 shall convert to non-exclusive;

	(b)
	in
the case of ICRT Licensed Product and ICRT/DF Licensed Product, the Licensed Product royalty rate and the Sublicense Revenue royalty rate shall become [+]
in all applicable circumstances; and

	(c)
	minimum
Licensed Product royalty shall cease. 

Upon
such conversion ICRT shall have the right to grant one or more licenses on non-exclusive terms to other parties and such terms shall be promptly disclosed to Biomira in writing. If
any such license and terms are more favourable to the other party, then Biomira shall have the right to have amended the terms of its non-exclusive license in like manner and ICRT shall
cooperate in doing so in a timely manner. 

5.     FINANCIAL PROVISIONS  

	5.1
	Where
Biomira or any of its Affiliates grants a sublicense under this Agreement, in addition to royalties payable pursuant to clause 5.4 in respect of Licensed Product Sold by
the sublicensee (or any of its Affiliates), Biomira shall pay to ICRT a royalty on any Sublicense Revenue received by Biomira or its Affiliates. The royalty rate shall be:

	(a)
	For
Sublicense Revenue derived from the United States, if at the time such Sublicense Revenue became due to Biomira or its Affiliates the manufacture, use or sale of Licensed Product
in the United States fell within the definition of:

	(i)
	ICRT
Licensed Product, the royalty rate shall be [+];

	(ii)
	ICRT/DF
Licensed Product, the royalty rate shall be [+]; and

	(iii)
	DF
Licensed Product, then for the avoidance of doubt, [+] shall be payable.

	(b)
	For
Sublicense Revenue derived from any country or territory of the Territory other than the United States, the royalty rate shall be [+]. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

8

  

	(c)
	Without
limitation and by way of illustration, if Sublicense Revenue is received by Biomira on the grant of a sublicense under the Licensed Patents in the United States or on the
completion of Phase II clinical trials of Licensed Product in the United States, for the purposes of this clause 5.1, the Sublicense Revenue shall be deemed derived from the United States.

	(d)
	If
Sublicense Revenue is not derived from any specific country or territory or the Sublicense Revenue is derived from both the United States and another country, the Sublicense
Revenue shall be apportioned between territories as is fair and reasonable.

	5.2
	Biomira
shall pay to ICRT the following minimum Sublicense Revenue royalty which shall be creditable against future Sublicense Revenue royalties:

	(a)
	[+]
on 1st January 2001; and

	(b)
	[+]
on 1st January 2002. 

No
part of the minimum Sublicense Revenue royalty shall be refundable. 

	5.3
	The
minimum Sublicense Revenue royalty paid pursuant to clause 5.2 shall be credited against the Sublicense Revenue royalties as follows:

	(a)
	the
Sublicense Revenue royalties calculated at the end of each Quarter and shown in the statement prepared pursuant to clause 5.6 shall be set against the minimum Sublicense
Revenue royalty paid to date;

	(b)
	no
Sublicense Revenue royalties shall be due from Biomira at the end of any Quarter in any Year unless and until the Sublicense Revenue royalties for that Year (calculated up to the
end of the relevant Quarter) together with the aggregate Sublicense Revenue royalties already due to ICRT in respect of all preceding Years exceeds the minimum Sublicense Revenue royalty paid to date,
in which case the excess shall be payable in full.

	5.4
	A
running royalty shall be paid on all Licensed Product which at any time during the Term is manufactured by or for Biomira, any of its Affiliates or any sublicensee of such person
and Sold by Biomira, any of its Affiliates or any sublicensee of such person, as the case may be, from the date of First Commercial Sale of such Licensed Product, and the running royalty shall be
calculated on the Net Sales Value of such Licensed Product in such country as follows:

	(a)
	For
Sales in the United States of:

	(i)
	ICRT
Licensed Product, the royalty rate shall be:

	(A)
	[+]
on the first [+] of Net Sales Value of such ICRT Licensed Product derived from the United States in a given Year; and

	(B)
	[+]
on the amount in excess of [+] of Net Sales Value of such ICRT Licensed Product derived from the United States in a given Year;

	(ii)
	DF
Licensed Product, the royalty rate shall be [+] (which obligation shall survive the termination of this Agreement for so long as the DF
Patents remain in force in the United States);

	(iii)
	ICRT/DF
Licensed Product, the royalty rate shall be [+]. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

9

 

	(b)
	For
Sales in any country of the Territory, other than the United States, of ICRT Licensed Product, the royalty rate shall be:

	(i)
	[+]
on the first [+] of Net Sales Value of such ICRT Licensed Product derived from such country in a given Year; and

	(ii)
	[+]
on the amount in excess of [+] of Net Sales Value of such ICRT Licensed Product derived from such country in a given
Year. 

For
the avoidance of doubt, [+] shall be payable on Sales of ICRT/DF Licensed Product or DF Licensed Product other than with respect to Sales in the United States as specified
in clause 5.4(a). 

	5.5
	(a)    Commencing
with the first Quarter after the First Commercial Sale of ICRT Licensed Product and/or ICRT/DF Licensed Product for a therapeutic application in any of the
Major Markets, Biomira shall during the Term (but subject to clause 7.4) pay ICRT, in the manner provided in clause 5.6 minimum Licensed Product royalty in the amounts specified below: 

	12 month period following Quarter

of First Commercial Sale
	 	minimum yearly royalty re therapeutic applications

	1	 	[+]
	2	 	[+]
	3	 	[+]
	4	 	[+]
	5	 	[+]
	thereafter, per year (12 month period)	 	[+]

The
minimum Licensed Product royalty specified in this clause 5.5(a) shall be creditable against future Licensed Product royalties payable in respect of Licensed Product for a therapeutic
application pursuant to this Agreement. 

	(b)
	Commencing
with the first Quarter after the First Commercial Sale of ICRT Licensed Product and/or ICRT/DF Licensed Product for a diagnostic-application in any of the Major Markets,
Biomira shall during the Term (but subject to clause 7.4) pay ICRT, in the manner provided in clause 5.6, minimum Licensed Product royalty in the amounts specified below: 

	12 month period following Quarter

of First Commercial Sale
	 	minimum yearly royalty re diagnostic applications

	1	 	[+]
	2	 	[+]
	3	 	[+]
	thereafter, per year (12 month period)	 	[+]

The
minimum Licensed Product royalties specified in this clause 5.5(b) shall be creditable against future Licensed Product royalties payable in respect of Licensed Product for a diagnostic
application pursuant to this Agreement. 

	(c)
	Notwithstanding
clauses 5.5(a) and (b) above, in the event that Biomira's license is rendered non-exclusive by ICRT under the provisions of this Agreement, there
will be no minimum Licensed Product royalty payments due under this Agreement. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

10

 
	5.6
	Royalties
(including any minimum Licensed Product royalties, if applicable) shall be paid as follows:

	(a)
	within
[+] days after each Quarter, Biomira shall send to ICRT a written statement identifying the ICRT agreement number allocated to this Agreement and
showing:

	(i)
	for
each sublicensee, brief details of each item of Sublicense Revenue and the amount of each item of Sublicense Revenue received during that Quarter;

	(ii)
	the
aggregate Sublicense Milestone Revenue paid up to the end of that Quarter;

	(iii)
	the
quantity of each type of Licensed Product (identified as either a therapeutic or diagnostic application) Sold by Biomira, any of its Affiliates or any sublicensee
of such person (showing separately any quantity so sold between Biomira, any of its Affiliates and any sublicensee of such person) during that Quarter in each country or territory, provided that Sales
of ICRT/DF Licensed Product and DF Licensed Product shall only be for the United States;

	(iv)
	Net
Sales Value in respect of each such type of Licensed Product in each country or territory, provided that Sales of ICRT/DF Licensed Product and DF Licensed Product
shall only be for the United States. Where any Licensed Product is Sold as part of a Kit the statement should show separately the Net Sales Value of each type of Kit (if applicable) as well as the
Licensed Product and the method used to determine the Net Sales Value of the Licensed Product;

	(v)
	the
aggregate Net Sales Values in respect of that quantity of Licensed Product;

	(vi)
	any
currency conversions, showing the rates used;

	(vii)
	any
further information necessary for the calculation of such Sublicense Revenue and Net Sales Value of Licensed Products and/or the royalties due to ICRT; and

	(viii)
	the
amount of the royalties (including any minimum Licensed Product royalties, if applicable) due to ICRT in respect of that Sublicense Revenue and quantity of
Licensed Products; and

	(b)
	subject
to clause 5.3 and the offset provisions in clause 7 and elsewhere in the Agreement, Biomira shall forthwith pay to ICRT the amount referred to in
(vii) above.

	5.7
	Biomira
shall promptly notify ICRT in writing of all submissions to appropriate regulatory authorities for approval to sell Licensed Product in any country, of the date such approvals
are granted, and the date of First Commercial Sale of such Licensed Products under this Agreement.

	5.8
	Unless
otherwise provided in this Agreement, all royalties or other sums payable under this Agreement shall be paid in the Currency. Where Sublicense Revenue or sales of Licensed
Products are invoiced or calculated in some other currency, conversion into the Currency shall be calculated by reference to the relevant foreign exchange buying rate for the currency in which they
are calculated of the Financial Times newspaper (and available at www.marketprices.ft.com) at the close of business in London on

	(a)
	in
the case of each sum payable under clauses 5.1 and 5.4, the last day of the Quarter or Year to which it relates;

	(b)
	in
the case of any other provision of this Agreement, the date on which it is payable.

	5.9
	Any
tax required under the laws of any government to be withheld or paid by Biomira, its Affiliates or sublicensees based on a royalty or other consideration due to ICRT under this
Agreement shall be deducted from the amount due to ICRT. Where available, Biomira shall 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

11

 

furnish
to ICRT a certificate or other documentary evidence executed by an appropriate official to enable ICRT to obtain relief from double taxation on such withholding or payment. 

	5.10
	All
payments due hereunder shall be paid in cleared funds by cheque or electronic transfer to such bank account in England as ICRT may specify from time to time. All costs of
transmission or currency conversion shall be borne by Biomira.

	5.11
	If
Biomira fails to pay in full any royalties or other sums payable under this Agreement on the date or within the period specified for payment, the amount outstanding shall bear
interest, both before and after any judgement, at the rate of [+] per annum above the base rate of National Westminster Bank PLC (or its successor) from time to time from that
date or the last day of that period until that amount is paid in full to ICRT.

	5.12
	If
any payment pursuant to this Agreement is required to be made on a day other than a Business Day, it may be made (and any currency calculation in respect of it shall be made) on
the next following Business Day, which shall be deemed to be the due date for payment.

	5.13
	For
the avoidance of doubt, royalties shall not be payable by Biomira in accordance with the preceding provisions more than once in respect of the same Sublicense Revenue or batch of
Licensed Products. 

6.     ACCOUNTS  

	6.1
	Biomira
shall:

	(a)
	keep,
and procure that each of its Affiliates keeps, and notwithstanding termination of this Agreement, maintains for at least four (4) Years from their making true and
accurate accounts and records in sufficient detail to enable the amount of all royalties or other sums payable under this Agreement to be determined; and

	(b)
	during
the Term, and thereafter if the said retention period of four (4) Years remains applicable to any particular records and accounts, at the reasonable request of ICRT and
(subject to clause 6.2) at the expense of ICRT, allow no more frequently than once per Year a qualified accountant from an accounting firm of international stature nominated by ICRT (or procure
that such a qualified accountant nominated by ICRT is allowed) to inspect during normal business hours, upon giving to Biomira a confidentiality undertaking which is reasonable in the circumstances,
those accounts and records which Biomira continues to be required to retain and to the extent that they relate to the calculation of those royalties or other sums, to take copies of them. Subject to
receiving not less than 30 (thirty) days written notice, Biomira shall at the request of ICRT assemble in one location all such relevant accounts and records of Biomira, its Affiliates and, so far as
it is reasonably able, those of its sublicensees.

	6.2
	If,
following any inspection pursuant to clause 6.1(b), ICRT's accountant certifies to ICRT and Biomira that the amount of the royalties paid in respect of any Quarter or Year
falls short of the amount of the royalties which were properly payable in respect of that Quarter or Year under this Agreement, Biomira shall (subject to clause 6.3) within
[+] days of the date of the certificate pay the shortfall to ICRT and, if the shortfall exceeds [+] of the amount properly payable, Biomira shall
also reimburse to ICRT in a timely manner the reasonable costs and expenses of ICRT in making the inspection.

	6.3
	If
within [+] of the date of any certificate produced pursuant to clause 6.2 Biomira notifies ICRT in writing that it disputes the certificate, the
dispute shall be referred to an independent Expert. The decision of any such Expert shall be issued in writing with his reasoning and in the absence of manifest error shall be final and binding and
his costs shall be borne as he 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

12

 
	

	may
determine to be fair and reasonable or, if he makes no such determination, by the parties equally. Any disputed sum which is determined by the Expert to
be payable shall be paid within [+] days of his determination.

	6.4
	The
provisions of clause 6.3 shall remain in full force and effect after the termination of this Agreement, for any reason until the settlement of all subsisting claims of ICRT
under this Agreement. 

7.     INTELLECTUAL PROPERTY PROTECTION AND PROCEEDINGS  

	7.1
	ICRT
shall have full discretion as to the prosecution of any ICRT Patent Applications, and any Patent or other protection obtained pursuant to any such application shall be or remain
the absolute properly of ICRT, subject to the following.

	7.2
	ICRT
shall take all reasonable steps necessary to prosecute in the Territory at its own cost (save those costs to be borne by Biomira as specified in this Agreement) the patent claims
in the ICRT Patent Applications which are relevant to the commercialization of Peptide and pay all requisite renewal fees to maintain the Licensed Patents in the Territory which are relevant to the
commercialization of Peptide. Biomira will provide legal assistance, at Biomira's expense, in connection with the prosecution in the United States of the patent claims in the ICRT Patent Applications,
which are relevant to the commercialization of Biomira's MUCI related Peptide products. For the avoidance of doubt, such legal assistance to be provided by Biomira shall include bearing the costs of
any interference action concerning any Licensed Patents. Biomira shall instruct its patent agents to keep ICRT fully and promptly informed of all actions that Biomira takes or proposes to take in the
United States in relation to such patent claims and ICRT shall be entitled to comment on or object to any such action (if ICRT objects to any such action, Biomira shall, on the written request of
ICRT, promptly desist from taking such action). ICRT shall keep Biomira fully and promptly informed of all action that ICRT takes or proposes to take in relation to the ICRT Patent Applications in any
and all jurisdictions.

	7.3
	Any
discoveries or inventions derived from Biomira Information shall be owned by Biomira and Biomira shall be responsible for securing patent protection for the same.

	7.4
	In
the event that ICRT does not wish in any country of the Territory to prosecute and maintain the Licensed Patents for Peptide and related inventions, in the manner prescribed by
this Agreement, it shall give Biomira written notice thereof and Biomira, at its option, such option to be exercised and notified to ICRT within [+] of receipt of notice from
ICRT, may undertake such patent prosecution and maintenance at its own cost and shall thereafter, notwithstanding any other provision in this Agreement to the contrary, not be required to pay any
royalties to ICRT with respect to Licensed Products manufactured or Sold in such country. Further, if Biomira assumes the prosecution and maintenance of the Licensed Patents in all of the Major
Markets or if ICRT ceases to prosecute and maintain the Licensed Patents in all of the Major Markets or if Biomira assumes the prosecution and maintenance of the Licensed Patents in certain of the
Major Markets and ICRT ceases to prosecute and maintain the Licensed Patents in the remaining Major Markets, then the minimum Licensed Product royalties payable pursuant to clauses 5.5(a) and
(b) shall cease to be payable. In the Year in which such minimum Licensed Product royalties cease to be payable, the minimum Licensed Product royalties shall be payable on a proportionate basis
for those months in and preceding which the last of the Licensed Patents in question ceased to be prosecuted and maintained by ICRT. Finally, if Biomira does not exercise such option to prosecute and
maintain the Licensed Patents in a particular country, ICRT shall have no further obligation with respect to the Licensed Patents in question in such country and such Licensed Patents in such country
shall cease to be Licensed Patents for the purposes of this Agreement. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

13

 
	7.5
	In
the event that ICRT or Biomira determines that a third party is making, using or selling a product which is within the Field in any country and within the scope of the Licensed
Patents in that country, such party shall promptly notify the other party in writing and the parties shall have a period of [+] days from the date of such notice of
alleged infringement to agree between themselves whether and under what conditions and procedures to enforce the infringed-upon Licensed Patent. If the parties do not agree, ICRT shall
have the first right to bring, at its own expense, an infringement action against any third party. If ICRT does not proceed with a particular patent infringement action within
[+] days thereafter, or if it notifies Biomira that it is abandoning such action Biomira, after notifying ICRT in writing, shall be entitled to take proceedings against
such infringer at its own expense.

	7.6
	In
the event that Biomira or an Affiliate of Biomira or a sublicensee is sued by a third party charging infringement of a patent because of the manufacture, use or sale by Biomira or
an Affiliate of Biomira or sublicensee of Licensed Product, or in the event a third party brings an action to obtain a declaration of Licensed Patent invalidity against ICRT and/or Biomira or an
Affiliate of Biomira or a sublicensee, each party will promptly notify the other in writing; and

	(a)
	the
named defendant(s) shall have the first right to defend said action(s) at its own cost and expense and to control ensuing litigation;

	(b)
	if
the named defendant elects not to defend the action(s), the other party may elect to defend the action(s) at its own cost and expense and to control the ensuing litigation.

	7.7
	In
both enforcement and defense actions the following shall apply:

	(a)
	during
the period of litigation Biomira may offset against Licensed Product royalties payable to ICRT for Sales in the country of such action Biomira's
out-of-pocket expenses in such action;

	(b)
	the
party conducting the suit shall have full control over its conduct, but the other party will reasonably assist and cooperate in such litigation upon request and be reimbursed for
reasonable out-of-pocket expenses (which shall exclude wages and salaries of that party's staff) incurred while providing such assistance to the requesting party;

	(c)
	any
recovery as a result of litigation and settlement thereof and any damages shall be the property of the party bearing the financial responsibility for such litigation;

	(d)
	in
the event of recovery by Biomira, after offsetting out-of-pocket costs incurred therewith and not recovered pursuant to clause 7.7(a), Biomira, shall
pay to ICRT the balance of such recovery up to the amount of royalties offset by Biomira under clause 7.7;

	(e)
	no
settlement, consent judgement or other voluntary final disposition of the action shall be entered into by Biomira or ICRT without the consent of the other party, such consent not
to be unreasonably withheld or delayed;

	(f)
	Biomira
shall include full details of all costs and expenses offset pursuant to clause 7.7(a) in each statement submitted to ICRT pursuant to clause 5.6.

	7.8
	The
parties shall, at the request of either of them and at the expense of the requesting party (save the other's in-house costs) but for no further consideration, enter
into such formal licenses relating to the Licensed Patents as may be necessary or desirable in accordance with the relevant law and practice in each part of the Territory for registration at the
relevant Patent Offices so that this present Agreement shall not in any circumstance be registered or recorded unless the parties are required to do so by law. If there shall be any inconsistencies
between the terms of any such formal license and the provisions of this Agreement, this Agreement shall prevail. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

14

 
	7.9
	(a)    Subject
to clause 7.9(c), if Biomira or any of its Affiliates challenges the validity or contests ICRT'S ownership of any of the Licensed Patents, ICRT shall
be entitled to terminate this Agreement forthwith.

	(b)
	Subject
to clause 7.9(c), if any non-Affiliated sublicensee of Biomira challenges the validity or contests ICRT ownership of any of the Licensed Patents, Biomira
shall promptly terminate such sublicense agreement.

	(c)
	Clauses
7.9(a) and (b) shall not apply in the case of a challenge to the validity of any of the Licensed Patents for Peptide and related inventions pursuant to an interference
action between a Licensed Patent and the DF Patents. 

8.     WARRANTIES, LIABILITY AND INDEMNITY  

	8.1
	ICRT
warrants to Biomira that:

	(a)
	it
has the authority to enter into this Agreement;

	(b)
	no
prior grant of rights has been made to any third party which is inconsistent with the rights granted under this Agreement.

	8.2
	Biomira
warrants to ICRT that it has the authority to enter into this Agreement.

	8.3
	Each
party acknowledges that, in entering into this Agreement, it does not do so in reliance on any warranty or other provision except as expressly provided in this Agreement, and any
conditions, warranties or other terms implied by statute or common law are excluded to the fullest extent permitted by law.

	8.4
	Without
limiting the scope of clause 8.3, ICRT does not give any warranty, representation or undertaking:

	(a)
	as
to the efficacy or usefulness of the Peptide or the Licensed Patents; or

	(b)
	as
to the volumes or quality of the Licensed Products which may be manufactured through the use of the Peptide or the Licensed Patents; or

	(c)
	that
any of the Licensed Patents is or will be valid or subsisting or that any of the applications within the Licensed Patents will proceed to grant; or

	(d)
	that
the manufacture, use or sale of the Peptide will not infringe the Intellectual Property or other rights of any other person.

	8.5
	Each
party shall be responsible for its own acts relating to the manufacture and use of Peptide and Licensed Product and neither shall indemnify the other for costs, expenses,
liability, damages and claims for any injury or death to persons or damage to or destruction of property or other loss arising out of or in connection with any Peptide or Licensed Product made or used
by cither party, save as expressly stated in this Agreement.

	8.6
	Biomira
agrees to indemnify and save harmless ICRT (for itself and for ICRF), its shareholders, directors, officers, employees, consultants, Affiliates and agents:

	(a)
	from
and against any and all actions, causes of action, claim, demands, awards and proceedings of every nature and kind whatsoever by whosoever made, bought or prosecuted; and

	(b)
	from
and against any and all loss, damage, cost or expense (including reasonable attorney's fees and expenses) suffered or incurred by ICRT (for itself and for ICRF), its
shareholders, directors, officers, employees, consultants, Affiliates or agents; 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

15

 

which
are based upon, arise out of or are connected with the use of the Licensed Patents by Biomira or any Affiliate or sublicensee of Biomira or any third party manufacturer of any Licensed Product
retained by Biomira or any Affiliate or sublicensee of Biomira or otherwise in connection with manufacture, use or sale of, or any other dealing in, any Licensed Product by or for Biomira or any of
its Affiliates or sublicensees, except to the extent that any such claim is based upon, arises out of or is connected with the breach or inaccuracy of any covenant, representation or agreement of ICRT
under this Agreement or any negligent act or omission of ICRT, ICRF or their respective shareholders, directors, officers, employees, consultants, Affiliates or agents. 

	8.7
	ICRT
agrees to indemnify and save harmless Biomira and its Affiliates and their respective shareholders, directors, officers, employees, consultants, and agents:

	(a)
	from
and against any and all actions, causes of action, claims, demands, awards and proceedings of every nature and kind whatsoever made, bought or prosecuted; and

	(b)
	from
and against any and all loss, damage, cost or expense (including reasonable attorney's fees and expenses) suffered or incurred by Biomira or its Affiliates or their respective
shareholders, directors, officers, employees, consultants, or agents; 

which
are based upon, arise out of or are connected with the breach or accuracy of any covenant, representation or agreement of ICRT under this Agreement or any negligent act or omission of ICRT or
ICRF or their respective shareholders, directors, officers, employees, consultants, Affiliates or agents, except to the extent that any such claim is based upon, arises out of or is connected with the
breach or inaccuracy of any covenant, representation or agreement of Biomira under this Agreement or any negligent act or omission of Biomira or its Affiliates or their respective shareholders,
directors, officers, employees, consultants, or agents. 

	8.8
	If
any claims contemplated by clauses 8.6 or 8.7 shall be asserted against any of the persons having a right to be indemnified pursuant to such sections (individually an "Indemnified
Party" and collectively the "Indemnified Parties"), the Indemnified Parties concerned shall promptly notify in writing the person or persons against whom such indemnity may be sought (individually an
"Indemnitor" and collectively the "Indemnitors") of the nature of such claim, and the Indemnitors shall, subject as hereinafter provided, be entitled (but not required) to assume the defense on behalf
of the Indemnified Parties of any suit or proceedings (including any governmental or regulatory investigation or proceeding) brought to enforce such claim. The Indemnitors shall be given full control
of any proceedings or negotiations in connection with such claim and shall be exclusively entitled to appoint and instruct legal advisers and counsel in connection with any such proceedings or
negotiations and to determine the forum for any such proceedings. The Indemnified Parties shall give the Indemnitors all reasonable assistance for the purpose of any such proceedings or negotiations
including, without limitation, using reasonable efforts to provide or make available documents and information and witnesses for attendance at examinations for discovery and trials. An Indemnified
Party shall have the right to employ separate counsel in any such suit and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of the Indemnified
Party unless the Indemnitor fails within a reasonable period of time to assume defense of such suit on behalf of the Indemnified Party. Except pursuant to a final award, the Indemnified Parties shall
not pay or accept any such claim or compromise any such proceedings or negotiations, without the consent of the Indemnitors (which consent shall not be unreasonably withheld). The Indemnified Parties
shall not do anything which would or might vitiate any policy of insurance or insurance cover which the Indemnified Parties may have in relation to any such claim or threatened claim, and no
indemnification shall be applicable to the extent that the Indemnified Parties recover any sums under any such policy or cover (which the Indemnified Parties shall use their best efforts to do). The
Indemnitors shall be entitled to require 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

16

 
	

	the
Indemnified Parties to take such steps as the Indemnitors may reasonably require to mitigate or reduce any loss of the Indemnified Parties.

	8.9
	Other
than with respect to the representations and warranties of ICRT set forth in clause 8.1:

	(a)
	neither
Party shall be liable to the other (except in circumstances of fraud, or death or personal injury caused through negligence) for any loss of profit or any special, indirect or
consequential damages;

	(b)
	the
amount of any claim for which ICRT would otherwise be liable under clause 8.7 shall not exceed the greater of £1,000,000 and total amounts paid by Biomira and
its Affiliates and their sublicensees under this Agreement up to the date of the claim.

	8.10
	Neither
party shall be liable for any delay or default in performance under this Agreement due to any cause beyond its reasonable control, including but not limited to acts of God or
the public enemy; laws, regulations, acts or requests of any government or any government officer or agent purporting to act under duly constituted authority; wars, floods, fires, storms, strikes,
lockouts, interruptions of transportation, freight embargoes, or failures, exhaustion or unavailability on the open market or delays in delivery of material, equipment or services necessary to the
performance of any provision hereof; or happening of any unforeseen act, misfortune or casualty by which performance hereunder is delayed or prevented.

	8.11
	Biomira
shall, for any in vivo clinical trials of Licensed Product and in any event upon the commercialization of any Licensed Product, at its own cost carry comprehensive general
liability insurance including product liability insurance which is commercially reasonable in the circumstances. Biomira shall provide ICRT with appropriate evidence of such insurance cover on
request. 

9.     DURATION AND TERMINATION  

	9.1
	This
Agreement shall come into force and replace and supercede the Original Agreement on the Effective Date and, unless terminated earlier for any reason, shall continue in force on a
country by county basis until the last to expire of Valid Claims of the Licensed Patents for Peptide.

	9.2
	ICRT
may terminate this Agreement by giving at least [+] prior written notice to Biomira:

	(a)
	if
Biomira commits any material breach of this Agreement and fails to remedy it within [+] after receiving from ICRT a written notice containing full
particulars of the breach and requiring it to be remedied; or

	(b)
	if
Biomira has a receiver, manager, administrator, or administrative receiver appointed of its undertaking, assets or income or any part thereof and such appointment is not vacated
within [+] of Biomira receiving written notice thereof or has passed a resolution for its winding-up or for an administration order or that a similar happening in
relation to Biomira has occurred at Biomira's principal place of business. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

17

  

	9.3
	Biomira
may terminate this Agreement by giving at least [+] prior written notice to ICRT:

	(a)
	if
ICRT commits any material breach of this Agreement and fails to remedy it within [+] after receiving from Biomira a written notice containing full
particulars of the breach and requiring it to be remedied; or

	(b)
	if
ICRT has a receiver, manager, administrator or administrative receiver appointed of its undertaking, assets or income or any part thereof and such appointment is not vacated within
[+] of Biomira receiving written notice thereof or has passed a resolution for its winding-up or for an administration order.

	9.4
	Biomira
may elect to terminate the commercialization and Sale of Licensed Product in respect of a given country upon giving not less than [+] written notice to
ICRT with its justification for such action. For the avoidance of doubt, upon any such termination in respect of a given country, that country shall cease to be part of the Territory and any Licensed
Patent in the relevant country shall cease to be a Licensed Patent for the purposes of this Agreement.

	9.5
	Biomira
shall promptly give written notice to ICRT in the event that a decision is made not to continue with the development and commercialization and Sale of the Peptide and Licensed
Product. Upon giving such notice, this Agreement shall terminate and all rights to the Peptide, and Licensed Patents shall revert to ICRT from the date of such notification.

	9.6
	The
rights given by this clause 9 to terminate this Agreement for any breach shall not prejudice any other right or remedy of either party in respect of the breach concerned or
any other breach. 

10.   EFFECTS OF TERMINATION  

	10.1
	Upon
the termination of this Agreement for any reason:

	(a)
	subject
to all the terms of this Agreement (including without limitation payment of royalties), Biomira shall be entitled following such termination to:

	(i)
	manufacture
for a period not exceeding [+] months any of the Licensed Products to the extent necessary to satisfy orders accepted before
termination; and

	(ii)
	sell,
use or otherwise dispose of (subject to payment of royalties under this Agreement) any unsold stocks of the Licensed Products; 

save
that clause 10.1(a)(i) "shall not apply where this Agreement has been terminated by ICRT pursuant to clause 9.2(b). 

	(b)
	subject
to paragraph (a) above, Biomira shall cease to exploit in any way, either directly or indirectly, the Licensed Patents, in so far and for as long as any of the Licensed
Patents remains in force.

	(c)
	subject
as provided in this clause 10.1 and clause 10.2, and except in respect of any accrued rights, neither party shall be under any further obligation to the other
under this Agreement.

	10.2
	The
termination of this Agreement howsoever arising will be without prejudice to the rights and duties of either party accrued prior to termination. The clauses in this Agreement
which expressly or impliedly have effect after termination will continue to be enforceable notwithstanding termination.

	10.3
	Upon
termination of this Agreement for any reason, Biomira will maintain exclusive possession and rights to Biomira Information. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

18

 

11.   CONFIDENTIALITY  

	11.1
	It
is understood that Peptide and details of New ICRT Patents provided by ICRT to Biomira are proprietary and confidential. Biomira hereby agrees to maintain the confidentiality of
all such ICRT information, except for such information which is necessary to be disclosed in connection with the Sale of Licensed Product, in compliance with any governmental regulation and approval
process relating to the production and sale of Licensed Product, and in connection with securing patent protection relating to Licensed Product.

	11.2
	It
is understood that Biomira Information developed by Biomira during the performance of activities subject to this Agreement is confidential to Biomira as is all information
provided by Biomira, its Affiliates or sublicensees pursuant to this Agreement. ICRT hereby agrees to maintain the confidentiality of all such information and will not disclose such information to any
person, except to employees or consultants of ICRT and ICRF on a "need-to-know" basis and then only if an appropriate confidentiality undertaking has been provided by such
employee or consultant to ICRT or ICRF and except for such information which is necessary to be disclosed in compliance with any governmental regulation. In the event that ICRT or ICRF is so requested
to disclose such information in compliance with an applicable governmental regulation, ICRT shall promptly notify Biomira in writing and use reasonable endeavours to allow Biomira reasonable
opportunity to oppose such disclosure requirement on ICRT or ICRF.

	11.3
	The
obligations of confidentiality herein shall not apply to information:

	(a)
	which
is possessed by or known to the receiving party (as evidenced by the receiving party's written records) prior to the supply or disclosure by the other Party;

	(b)
	which
has been or shall be voluntarily disclosed or transferred to the public through no material fault or omission by the receiving party (but only after and only to the extent that
it is published or otherwise becomes part of the public domain);

	(c)
	which
is lawfully received by the receiving party from a third party (as evidenced by the receiving party's written records) not prohibited from disclosing it to the receiving party;
or

	(d)
	which
was subsequently and independently developed by employees of the receiving party (as evidenced by the receiving party's written records) who had no knowledge of the disclosed
information.

	11.4
	Except
as required by law or any applicable regulatory authority, neither ICRT or Biomira shall release any publicity, news release, or other public announcement, written or oral,
whether to the public press, or stockholders, or otherwise, relating to this Agreement, to any amendment hereto or to performance hereunder without the prior written approval of the other party, which
consent shall not be unreasonably withheld and if given shall be given promptly.

	11.5
	The
parties' obligations of confidentiality with respect to Biomira Information shall expire ten (10) years from the date of its receipt of such information and shall survive
the termination of this Agreement. 

12.   ENTIRE AGREEMENT  

	12.1
	This
Agreement contains the entire agreement between the parties with respect to the subject matter herein and supersedes and replaces all prior communications, representations,
warranties, stipulations, undertakings and agreements whether oral or written between the parties.

	12.2
	Without
limitation to clause 12.1, this Agreement supersedes and replaces the Original License with effect from the Effective Date. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

19

 

13.   NATURE OF AGREEMENT  

	13.1
	Except
as specifically provided for in this Agreement, neither party shall be entitled to assign its rights or obligations under this Agreement without the prior written consent of
the other party, which consent shall not be unreasonably withheld, provided however that such consent shall not be required in the event that the assignment is to an Affiliate of either party (though
in such case the original assigning party shall remain liable for the performance by the assignee(s) of its obligations under this Agreement) or is made in connection with the transfer of all or
substantially all of the business of either party.

	13.2
	Nothing
in this Agreement shall create, or be deemed to create, a partnership, or the relationship of principal and agent, between the parties.

	13.3
	This
Agreement may not be modified except by an instrument in writing signed by the duly authorised representatives of the parties.

	13.4
	Nothing
in the Agreement is intended to confer any benefit on any third party (whether referred to herein by name, class or description or otherwise) or any right to enforce a term
contained in this Agreement and the Contracts (Rights of Third Parties) Act shall not apply to this Agreement.

	13.5
	No
failure or delay by either party in exercising any of its rights under this Agreement shall be deemed to be a waiver of that right, and no waiver by either party of a breach of
any provision of this Agreement shall be deemed to be a waiver of any subsequent breach of the same or any other provision.

	13.6
	If
any provision of this Agreement is held by any court or other competent authority to be invalid or unenforceable in whole or in part, the other provisions of this Agreement and
the remainder of the affected provision shall continue to be valid.

	13.7
	The
rights of ICRT under this Agreement are cumulative and in addition to any other right or remedy available to it at law or in equity. 

14.   APPLICABLE LAW AND JURISDICTION  

	14.1
	Except
as provided in clause 14.2, this Agreement shall be governed by and constituted in accordance with the laws of the domicile of the defendant in any given proceeding and
except where this Agreement provides for a dispute to be settled by the Expert, the parties hereby submit to the exclusive jurisdiction of the courts of such domicile for such proceeding.

	14.2
	Any
question arising out of this Agreement as to the construction or effect of any of the Licensed Patents shall be decided in accordance with the laws of the country in which the
Licensed Patent in question has been granted or filed. 

15.   NOTICES AND SERVICE  

	15.1
	All
notices and communications shall be in writing and addressed to the parties at the relevant address stated at the beginning of this Agreement (or such other address as may be
notified from time to time) marked for the attention of both the President and the General Counsel in the case of Biomira and to the Director at ICRT. All notices and communications shall be deemed to
have been duly served:

	(a)
	if
delivered by hand, when left at the proper address for service;

	(b)
	if
given by prepaid first class post, [+] after posting (excluding any day which is not a Business Day); 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

20

 

	(c)
	if
given by facsimile, at the time of transmission provided that a confirming copy is sent by post or hand as provided herein within [+] after transmission; 

provided
that where in the case of delivery by hand or transmission by facsimile such delivery or transmission occurs either after 4.00 p.m. on a Business Day or on a day which is not a
Business Day, service shall be deemed to occur at 10.00 a.m. on the next following Business Day (such times being local time at the address of the recipient). 

	15.2
	Service
of any legal proceedings concerning or arising out of this Agreement shall be effected by either party by causing the document in question to be delivered to the other party
at its registered or principal office, or any other address which is notified in writing from time to time to the party serving the proceedings. 

16.   MISCELLANEOUS  

	16.1
	Each
party shall from time to time do all such acts and execute all such documents as may be reasonably necessary in order to give effect to the provisions of this Agreement.

	16.2
	Except
as otherwise provided in this Agreement, the parties shall bear their own costs of and incidental to the preparation, execution and implementation of this Agreement.

	16.3
	This
Agreement may be executed in more than one counterpart and shall come into force once each party has executed such a counterpart in identical form and exchanged it with the
other party. 

	For Imperial Cancer Research Technology Limited	 	 
	

/s/  JOHN K. WALL      
 Director	
 	

 
	

For Biomira Inc.	
 	

 
	

/s/  ROBERT D. AUBREY      
 VP Marketing	
 	

 
	

/s/
 Director Intellectual Property Management	
 	

 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

21

  

 
 

SCHEDULE 1
  
    THE LICENSED PATENTS    
    

	Country
 
	 	Appln. No.

Pub'n No.

Patent No.
 
	 	Filing date+

Pub'n date*

Grant date
 
	 	Status
 
	 	 

	UK	 	[+]	 	[+]	 	Abandoned	 	 
	 	 	—	 	—	 	 	 	 
	 	 	—	 	—	 	 	 	 
	UK	 	[+]	 	[+]	 	Abandoned	 	 
	 	 	—	 	—	 	 	 	 
	 	 	—	 	—	 	 	 	 
	USA	 	[+]	 	[+]	 	Abandoned	 	 
	 	 	—	 	—	 	 	 	 
	 	 	—	 	—	 	 	 	 
	UK	 	[+]	 	[+]	 	Abandoned	 	 
	 	 	—	 	—	 	 	 	 
	 	 	—	 	—	 	 	 	 
	WO1	 	[+]	 	[+]	 	Spent	 	 
	 	 	[+]	 	[+]	 	 	 	 
	 	 	—	 	—	 	 	 	 
	CA	 	[+]	 	[+]	 	Granted	 	Claims granted to antibodies, peptides and nucleic acid fragments
	 	 	—	 	—	 	 	 	 
	 	 	[+]	 	[+]	 	 	 	 
	EP	 	[+]	 	[+]	 	Granted	 	Claims granted to use of polypeptides in therapy and diagnosis
	 	 	[+]	 	[+]	 	 	 	 
	 	 	[+]	 	[+]	 	 	 	 
	EP(Div)	 	[+]	 	[+]	 	Pending	 	Claims pending to nucleotides-awaiting examination
	 	 	[+]	 	[+]	 	 	 	 
	 	 	—	 	—	 	 	 	 
	JP	 	[+]	 	[+]	 	Abandoned	 	 
	 	 	—	 	—	 	 	 	 
	 	 	—	 	—	 	 	 	 
	JP	 	[+]	 	[+]	 	Pending	 	Claims pending
	 	 	—	 	—	 	Divisional filed	 	to peptides and nucleic fragments
	JP	 	[+]	 	[+]	 	Divisional filed	 	Antibodies
	USA	 	[+]	 	[+]	 	Abandoned	 	 
	 	 	—	 	—	 	 	 	 
	 	 	—	 	—	 	 	 	 
	USA	 	[+]	 	[+]	 	Abandoned	 	 
	 	 	—	 	—	 	 	 	 
	 	 	—	 	—	 	 	 	 
	USA	 	[+]	 	[+]	 	Pending	 	Claims related to peptides
	 	 	—	 	—	 	 	 	 
	 	 	—	 	—	 	 	 	 
	USA	 	[+]	 	[+]	 	Granted [+]	 	Antibodies [+]
	USA	 	[+]	 	[+]	 	Pending	 	Peptides
	USA	 	[+]	 	[+]	 	Granted [+]	 	Nucleotides [+]

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

22

 

	[+]	 	 	 	 	 	 	 	 
	 	 	—	 	—	 	 	 	 

	+
	Effective
filing date in (      )—i.e. via PCT.

	*
	Effective
publication date in (      )—i.e. via PCT.

	1
	

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

23

 
 
 

SCHEDULE A    
    

Patent Portfolio

	Country

(Application Date)
 
	 	Status
 
	 	Serial No./Patent No.
 

	United States [+]	 	Abandoned

(Priority date)	 	[+]
	United States - Continuation-in-part of [+]	 	Issued on [+]

(Group III claims)	 	[+]
	United States - Divisional [+]	 	Pending	 	[+]

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR ONFIDENTIALITY PURPOSES 

24

 
 
 

Appendix A: Patents Included in Patent Rights    
    

United
States Patent Number [+]. 

United
States Patent Number [+]. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

25

 
 
 

Patent Schedule (as of Feb 10, 2004)-
  Cancer Research Technology License Agreement of Nov 19, 2001
  (MUC-1 peptides)    

Note that the list represents currently active members of the pertinent patent family however not all patents/pending applications will contain
claims covering the licensed technology  

	 
	 	Application/patent number
 
	 	Status
 

	US:	 	[+]	 	Granted
	 	 	[+]	 	Granted
	 	 	[+]	 	Granted
	 	 	[+]	 	Pending
	Europe:	 	[+]	 	Granted
	 	 	[+]	 	Pending
	Japan:	 	[+]	 	Pending
	 	 	[+]	 	Pending
	Canada:	 	[+]	 	Granted

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

26

QuickLinks

AMENDED AND RESTATED LICENSE AGREEMENT dated 14th November 2000

SCHEDULE 1 THE LICENSED PATENTS

SCHEDULE A

Appendix A: Patents Included in Patent Rights

Patent Schedule (as of Feb 10, 2004)- Cancer Research Technology License Agreement of Nov 19, 2001 (MUC-1 peptides)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]